Ensartinib has shown significantly greater efficacy in ALK positive non-small cell lung cancer patients when compared to crizotinib (25.8 and 12.7 months respectively) and clinical trials are currently in place for pHGGs harboring ALK, NTRK and ROS1 fusions (255). Here, ALK is linked to non-small cell lung carcinoma.